AKBA Akebia Therapeutics Inc.

3.66
-0.4  -10%
Previous Close 4.06
Open 4.2
Price To Book 0.84
Market Cap 435,041,270
Shares 118,863,735
Volume 1,991,178
Short Ratio
Av. Daily Volume 771,080
Stock charts supplied by TradingView

NewsSee all news

  1. Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease

    Each Study Met Primary Endpoint at 24-Weeks and Showed Vadadustat's Effect on Hemoglobin Was Sustained Through to 52-Weeks Data Presented at the American Society of Nephrology (ASN) Kidney Week 2019 by Mitsubishi

  2. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired employees options to

  3. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees options to

  4. Akebia Therapeutics Announces Full Enrollment of its Global Phase 3 Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

    INNO2VATE and PRO2TECT now fully enrolled; Company continues to expect to report top-line study results in Q2 of 2020 and mid-2020, respectively, subject to accrual of MACE Akebia Therapeutics, Inc. (NASDAQ:AKBA) today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated in 2019.
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Phase 2 trial data due 2019.
Vadadustat - FO2RWARD
Renal anemia
Approved Sept 5, 2014.
Auryxia
Hyperphosphatemia
Phase 3 data due 2Q 2020.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3 data due mid-2020.
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
sNDA FDA Approval announced November 7, 2017.
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients

Latest News

  1. Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease

    Each Study Met Primary Endpoint at 24-Weeks and Showed Vadadustat's Effect on Hemoglobin Was Sustained Through to 52-Weeks Data Presented at the American Society of Nephrology (ASN) Kidney Week 2019 by Mitsubishi

  2. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired employees options to

  3. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees options to

  4. Akebia Therapeutics Announces Full Enrollment of its Global Phase 3 Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

    INNO2VATE and PRO2TECT now fully enrolled; Company continues to expect to report top-line study results in Q2 of 2020 and mid-2020, respectively, subject to accrual of MACE Akebia Therapeutics, Inc. (NASDAQ:AKBA) today